Trilogy Capital Inc. lifted its position in shares of Veeva Systems Inc. (NYSE:VEEV – Free Report) by 17.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,653 shares of the technology company’s stock after buying an additional 3,199 shares during the quarter. Trilogy Capital Inc.’s holdings in Veeva Systems were worth $3,843,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. SHP Wealth Management bought a new stake in Veeva Systems during the fourth quarter valued at about $26,000. Newbridge Financial Services Group Inc. boosted its stake in shares of Veeva Systems by 322.6% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 131 shares of the technology company’s stock worth $29,000 after acquiring an additional 100 shares during the period. Activest Wealth Management boosted its stake in shares of Veeva Systems by 3,175.0% in the fourth quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock worth $29,000 after acquiring an additional 127 shares during the period. MV Capital Management Inc. purchased a new stake in shares of Veeva Systems during the fourth quarter worth about $30,000. Finally, Reflection Asset Management purchased a new stake in shares of Veeva Systems during the fourth quarter worth about $32,000. Institutional investors own 88.20% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts recently commented on VEEV shares. Guggenheim started coverage on Veeva Systems in a report on Thursday, July 23rd. They issued a “buy” rating and a $232.00 price target on the stock. Raymond James Financial reaffirmed an “outperform” rating and set a $225.00 price objective on shares of Veeva Systems in a report on Thursday, June 4th. TD Cowen reiterated a “buy” rating on shares of Veeva Systems in a research report on Thursday, June 4th. Wall Street Zen downgraded shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Monday. Finally, Robert W. Baird upped their target price on shares of Veeva Systems from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $247.08.
Veeva Systems Trading Up 1.1%
NYSE:VEEV opened at $206.11 on Tuesday. The business’s 50-day moving average is $179.48 and its 200 day moving average is $179.88. Veeva Systems Inc. has a 12 month low of $148.05 and a 12 month high of $310.50. The company has a market capitalization of $33.48 billion, a P/E ratio of 36.74, a P/E/G ratio of 0.88 and a beta of 0.94.
Veeva Systems (NYSE:VEEV – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The technology company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The business had revenue of $882.95 million during the quarter, compared to analysts’ expectations of $857.73 million. During the same quarter last year, the business posted $1.97 EPS. The firm’s revenue for the quarter was up 16.3% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. On average, research analysts forecast that Veeva Systems Inc. will post 6.65 earnings per share for the current year.
About Veeva Systems
Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.
Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.
Further Reading
- Five stocks we like better than Veeva Systems
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
